Literature DB >> 2612541

Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.

C Silvain1, S Bouquet, J P Breux, B Becq-Giraudon, M Beauchant.   

Abstract

Plasma and ascitic fluid concentrations of ofloxacin were determined in 12 cirrhotic patients after a single dose and repeated 200 mg oral doses. The single dose kinetics were compared to those obtained in 12 healthy volunteers. Mean plasma elimination half-life was 11.6 h in cirrhotics and 7.0 h in controls. Mean total clearance was 2.3 times lower in patients than in controls, due to a significant decrease of renal clearance of the drug, unrelated to creatinine clearance. Mean apparent volume of distribution was 1.2 l/kg in patients and 1.8 l/kg in controls. Estimated by the ratio of AUC in peritoneal fluid and plasma, ascitic fluid penetration was 80% after the first oral dose. Ascitic fluid concentrations equaled corresponding plasma concentrations after 10 h, without pronounced accumulation of ofloxacin in ascites. We may conclude that, in cirrhotic patients with normal serum creatinine, a significant impairment of renal tubular handling of ofloxacin could be observed and led to a delayed elimination half-life of the drug. Because of its broad spectrum of activity, low side-effect profile, and large ascitic fluid penetration after oral administration, ofloxacin appears to be a new therapeutic approach of severe infections in cirrhotic patients, in particular spontaneous bacterial peritonitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612541     DOI: 10.1007/bf00679781

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  The adverse effects of fluoroquinolones.

Authors:  C R Smith
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

2.  Decreased erythrocyte penetration of pefloxacin in cirrhotic patients.

Authors:  C Silvain; J P Breux; E Rochard; S Bouquet; B Becq-Giraudon; M Beauchant
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  The use of gentamicin in peritoneal dialysis. I. Pharmacologic results.

Authors:  T Smithivas; P J Hyams; R Matalon; M S Simberkoff; J J Rahal
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

Review 4.  Drug metabolism in patients with liver disease.

Authors:  J W Secor; S Schenker
Journal:  Adv Intern Med       Date:  1987

5.  Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study.

Authors:  M A Papadakis; A I Arieff
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

6.  Clinical use of the quinolones.

Authors:  H C Neu
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

7.  Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis.

Authors:  D N Gerding; W H Hall; E A Schierl
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

8.  Spontaneous bacterial peritonitis.

Authors:  J C Hoefs; H N Canawati; F L Sapico; R R Hopkins; J Weiner; J Z Montgomerie
Journal:  Hepatology       Date:  1982 Jul-Aug       Impact factor: 17.425

9.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

10.  Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections.

Authors:  J Felisart; A Rimola; V Arroyo; R M Perez-Ayuso; E Quintero; P Gines; J Rodes
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

View more
  9 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Spontaneous peritonitis due to Brucella melitensis in a patient with cirrhosis.

Authors:  F Demirkan; H E Akalin; H Simşek; E Ozyilkan; H Telatar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

4.  Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

Authors:  S C Flor; M C Rogge; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 5.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

6.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01

Review 7.  Pharmacokinetics of temafloxacin after multiple oral administration.

Authors:  G R Granneman
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

8.  Pharmacokinetics of temafloxacin in patients with liver impairment.

Authors:  G R Granneman; G Mahr; C Locke; P Nickel; W Kirch; W Fabian; M Kinzig; K G Naber; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

9.  Effect of cimetidine on the pharmacokinetics of temafloxacin.

Authors:  F Sörgel; G R Granneman; U Stephan; C Locke
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.